A Phase I/IIa Clinical Trial to Evaluate Safety and Adrenal Uptake of Para-Chloro-2-[<sup>18</sup>F]Fluoroethyletomidate in Healthy Volunteers and Patients with Primary Aldosteronism
Daniel Gillett(Cambridge University Hospitals NHS Foundation Trust), Mark Gurnell(University of Cambridge), István Boros(University of Cambridge), James MacFarlane(University of Cambridge), Iosif Mendichovszky(Cambridge University Hospitals NHS Foundation Trust), Russell Senanayake(University of Cambridge), Luigi Aloj(University of Cambridge), August Palma, Per Hellman(Uppsala University Hospital), Gunnar Antoni(Uppsala University), Waiel Bashari(University of Cambridge), Franklin I. Aigbirhio(University of Cambridge), Anders Sundín(Uppsala University), Lihua Hu, Morris J. Brown(St Bartholomew's Hospital), Inês Harper(Addenbrooke's Hospital), Heok Cheow(Cambridge University Hospitals NHS Foundation Trust), Matthew Hird(University of Cambridge)
Cited by 11
Related Papers
Traumatic brain injury: progress and challenges in prevention, clinical care, and research
|The Lancet Neurology|2022|1.3k
K <sup>+</sup> Channel Mutations in Adrenal Aldosterone-Producing Adenomas and Hereditary Hypertension
|Science|2011|983
Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort
|The Lancet Diabetes & Endocrinology|2017|951
Mapping neurotransmitter systems to the structural and functional organization of the human neocortex
|Nature Neuroscience|2022|773